Search through all our worldwide HIV and AIDS news and features, using the topics below to filter your results by subjects including HIV treatment, transmission and prevention, and hepatitis and TB co-infections.

Hepatitis and HIV news

Show

From To
U.S. Food and Drug Administration Approves Gilead’s Harvoni® (Ledipasvir/Sofosbuvir), the First Once-Daily Single Tablet Regimen for the Treatment of Genotype 1 Chronic Hepatitis C

Harvoni’s efficacy has been established in patients with chronic hepatitis C virus (HCV) genotype 1 infection, with a treatment duration of eight, 12 or 24 weeks depending on prior treatment history, cirrhosis status and baseline viral load. Eight weeks of treatment with Harvoni can be considered for treatment-naïve patients without cirrhosis who have baseline HCV viral load below 6 million IU/mL.

Published
10 October 2014
From
Gilead press release
Thousands of Hep C patients in Alexandria wait in long lines to receive Sovaldi

Thousands of Hepatitis C virus patients have flooded two medical centers in Alexandria in hopes of receiving the new Hep C Sovaldi drug, after the health ministry said it will be providing it for patients.

Published
10 October 2014
From
Egypt Independent
Sovaldi ‘unaffordable’ says NHS documents

Senior health officials may have to bar Gilead’s new hepatitis C pill Sovaldi from being funded on the NHS after new data shows it would cost the health service £1 billion a year to fund.

Published
08 October 2014
From
Pharmafile
In a surprise move, Bristol-Myers drops U.S. approval plans for hep C drug

After sizing up the competitive landscape as rival Gilead ($GILD) races ahead with a new combo treatment, Bristol-Myers has opted to drop its application to gain an approval in the U.S. for asunaprevir, its NS3/4A protease inhibitor, and won't go after an OK to use a combination of daclatasvir and asunaprevir for genotype 1b patients.

Published
07 October 2014
From
Fierce Biotech
CVS: One In 12 Hepatitis C Patients Not Adhering To $1,000/Day Pill

Over 8 percent of hepatitis C patients taking Sovaldi (sofosbuvir; Gilead) are failing to complete their full, 12-week course of drug therapy, a dropout rate roughly four times that observed in clinical trials. By discontinuing the drug, shown to have a 90+% cure rate, these patients (and their insurance providers) are incurring health care costs of $28,000 or $56,000, without knowing if they are rid of the virus.

Published
07 October 2014
From
Forbes
Most Spanish patients coinfected with HIV/HCV called difficult to cure

Most patients coinfected with HIV and hepatitis C virus infection at a clinic in Spain were considered “difficult to cure” primarily because of their HCV genotype and other factors, according to data presented at the AASLD/EASL Special Conference on Hepatitis C.

Published
07 October 2014
From
Healio
New Hepatitis C Treatment Too Pricey For All Patients

There's a brand-new drug to treat Hepatitis C, but only a small percentage of patients enrolled in the state's Medicaid program are receiving it. The drug Sovaldi is supposed to work quicker and with fewer side effects than other medications that treat HCV. Arizona's Medicaid program limits coverage for effective but expensive drug.

Published
07 October 2014
From
KJZZ Radio
People with hepatitis B who have cirrhosis should be prioritised for liver cancer screening

Liver cancer screening for people with hepatitis B virus (HBV) infection should be targeted at those with cirrhosis, according to the results of a systematic review and meta-analysis

Published
02 October 2014
By
Michael Carter
Investigating an outbreak of hepatitis C virus among MSM without HIV

Given the reports about the high-risk practices taking place in London (and likely other cities in high-income countries), it is likely that cases of sexually transmitted HCV are also occurring in some HIV-negative MSM. To investigate this possibility, researchers in London reviewed health-related information collected from HIV-negative patients who sought care at selected clinics in that city.

Published
01 October 2014
From
CATIE
J&J makes a splash in hep C with a $1.75B deal for Alios

Johnson & Johnson ($JNJ) is taking a deep dive into antivirals, trading $1.75 billion for private biotech Alios BioPharma to get its hands on a midstage treatment and some early assets that could expand its share of the blockbuster hepatitis C market.

Published
01 October 2014
From
Fierce Biotech

Filter by country